Everything You Need to Know About Type 1 vs Type 2 DM for Step 1

Diabetes mellitus is one of those Step 1 topics that feels “basic”… until you miss a question because you mixed up autoimmune beta-cell destruction with insulin resistance, or forgot which antibodies point to Type 1. This post is your high-yield, side-by-side deep dive on Type 1 vs Type 2 diabetes mellitus—definition, pathophys, presentation, diagnosis, treatment, and the associations USMLE loves to test.

---

Big Picture: What “Diabetes Mellitus” Actually Means

Diabetes mellitus (DM) is chronic hyperglycemia due to:

• Absolute insulin deficiency (Type 1) and/or
• Insulin resistance with relative insulin deficiency (Type 2)

Hyperglycemia leads to:

• Acute emergencies: DKA, HHS
• Chronic complications: microvascular (retina, kidney, nerves) + macrovascular (CAD, stroke, PAD)

💡

First Aid cross-reference: Endocrine section → Diabetes mellitus, plus the Pharm section for insulin and oral agents.

---

Type 1 vs Type 2: The Highest-Yield Comparison Table

---

Type 1 Diabetes Mellitus (T1DM)

Definition (Step phrasing)

Type 1 DM is autoimmune destruction of pancreatic $\beta$ cells, causing absolute insulin deficiency.

Pathophysiology: What’s actually happening?

• T-cell–mediated autoimmune damage (Type IV hypersensitivity conceptually)
• Autoantibodies are markers (useful diagnostically), not necessarily the primary mediators
• Islet lymphocytic infiltration = insulitis (classic histology buzzword)

Why DKA happens (and why it’s so testable)

Without insulin:

• Glucose can’t enter insulin-dependent tissues → hyperglycemia
• Body “thinks” it’s starving → lipolysis → free fatty acids → liver makes ketones
• Ketones (acetoacetate, $\beta$-hydroxybutyrate) → anion gap metabolic acidosis

💡

First Aid cross-reference: DKA page + acid–base disorders (anion gap acidosis).

Clinical presentation (classic vignette)

• Polyuria, polydipsia, weight loss
• Fatigue, blurry vision
• Often presents with DKA:
  • Abdominal pain, vomiting
  • Kussmaul respirations
  • Fruity breath (acetone)
  • Dehydration, tachycardia

Diagnosis: what to know for USMLE

Diabetes can be diagnosed by any of the following (typically confirmed on repeat testing unless unequivocal symptoms):

• A1c $\ge 6.5\%$
• Fasting plasma glucose $\ge 126$ mg/dL
• 2-hour OGTT $\ge 200$ mg/dL
• Random glucose $\ge 200$ mg/dL + classic symptoms

Clues pointing specifically to Type 1:

• Positive anti-GAD (most commonly tested), anti-islet cell, anti-insulin antibodies
• Low C-peptide (endogenous insulin marker)

💡

High-yield pearl: Exogenous insulin does not come with C-peptide. Endogenous insulin secretion releases insulin + C-peptide (cleavage of proinsulin).

Treatment (Step 1 focus)

• Insulin therapy is mandatory
  • Basal + bolus regimens are typical (e.g., long-acting + rapid-acting)
• Patient education: hypoglycemia recognition, carb counting, sick day rules

Major adverse effect: hypoglycemia

• Confusion, sweating, tremor, palpitations
• Severe: seizures, coma
• Treat: oral glucose if awake; glucagon IM if unable to take PO; IV dextrose in hospital

High-yield associations

• Other autoimmune diseases:
  • Hashimoto thyroiditis
  • Addison disease
  • Celiac disease
• HLA-DR3 and HLA-DR4
• Viral trigger theories exist (Step may mention) but autoimmune mechanism is the core.

---

Type 2 Diabetes Mellitus (T2DM)

Definition (Step phrasing)

Type 2 DM is insulin resistance with progressive $\beta$-cell dysfunction, causing relative insulin deficiency.

Pathophysiology: the “insulin resistance → burnout” story

Early disease:

• Insulin resistance (muscle, liver, adipose) → pancreas compensates with hyperinsulinemia
• Therefore C-peptide tends to be high initially

Over time:

• $\beta$-cells fail (glucotoxicity, lipotoxicity, islet inflammation) → insulin output falls
• Many patients eventually need insulin

Histology association you should recognize

• Islet amyloid deposition (amylin/IAPP-derived) is associated with T2DM

💡

First Aid cross-reference: Endocrine pathology for T2DM histology and metabolic syndrome.

Clinical presentation: classic vignette

• Often asymptomatic for years; found on screening
• Polyuria/polydipsia can occur when very high glucose
• Recurrent infections (candida), slow wound healing
• Neuropathy symptoms (burning feet) may be an early complaint
• Physical clue: acanthosis nigricans (velvety hyperpigmentation in neck/axilla) from hyperinsulinemia

Diagnosis

Same glycemic thresholds as T1DM.

Clues pointing specifically to Type 2:

• Obesity, sedentary lifestyle, family history
• No autoimmune antibodies
• High/normal C-peptide early

Complication risk profile (Step nuance)

• HHS (hyperosmolar hyperglycemic state) is classic for T2DM:
  • Very high glucose, dehydration, AMS
  • Minimal/absent ketones (some insulin suppresses ketogenesis)
  • High serum osmolality

Treatment (Step 1 + Step 2 high yield)

Think in layers:

1) Lifestyle (always)

• Weight loss, exercise
• Diet changes
• Treat comorbidities (BP, lipids)

2) First-line medication (classic Step answer)

• Metformin (unless contraindicated)
  • Mechanism: decreases hepatic gluconeogenesis; increases insulin sensitivity
  • Adverse effects: GI upset; lactic acidosis (rare but classic)
  • Contraindication: significant renal dysfunction (Step commonly tests “risk of lactic acidosis”)

3) Add-on agents (commonly tested classes)

• GLP-1 receptor agonists (e.g., semaglutide, liraglutide)
  • Increase glucose-dependent insulin release, decrease glucagon, slow gastric emptying
  • Weight loss benefit
  • Notable adverse effects: GI, risk of pancreatitis (classically tested)
• SGLT2 inhibitors (e.g., empagliflozin, canagliflozin)
  • Increase urinary glucose excretion
  • Benefits: some have strong CV/renal outcome data (Step 2-ish)
  • Adverse effects: genital mycotic infections, UTIs; volume depletion; euglycemic DKA (high yield!)
• Sulfonylureas (e.g., glyburide, glipizide)
  • Close KATP channels → depolarization → insulin release
  • Adverse effects: hypoglycemia, weight gain
• Thiazolidinediones (e.g., pioglitazone)
  • Activate PPAR-$\gamma$ → increase insulin sensitivity
  • Adverse effects: weight gain, edema, HF exacerbation; fractures (often tested)

4) Insulin (when needed)

• If A1c is very high at diagnosis, symptomatic hyperglycemia, or progressive $\beta$-cell failure

💡

First Aid cross-reference: Pharm section tables for diabetes drugs (mechanisms + side effects).

High-yield associations

• Metabolic syndrome features cluster with T2DM:
  • Central obesity
  • Hypertension
  • Dyslipidemia (often ↑TG, ↓HDL)
  • Impaired fasting glucose
• Acanthosis nigricans = insulin resistance clue
• Islet amyloid deposition

---

DKA vs HHS: Rapid-Fire Differentiation (Frequently Tested)

Both are treated with:

• IV fluids
• Insulin (carefully)
• Electrolyte management (especially potassium)

💡

High-yield potassium concept: Insulin drives K into cells. In DKA, total body K is depleted even if serum K is normal/high initially.

---

Microvascular vs Macrovascular Complications (DM in general)

Microvascular (from chronic hyperglycemia)

• Retinopathy
• Nephropathy (classically nodular glomerulosclerosis/Kimmelstiel-Wilson lesions)
• Neuropathy

Mechanism you should be able to say:

• Nonenzymatic glycation → advanced glycation end products (AGEs) → basement membrane thickening, oxidative stress, inflammation

Macrovascular

• Accelerated atherosclerosis → MI, stroke, PAD
• This is why aggressive control of BP, LDL, smoking matters (very Step 2 relevant)

💡

First Aid cross-reference: Vascular pathology + renal pathology for diabetic nephropathy.

---

High-Yield “Trick Points” USMLE Likes

1) C-peptide = endogenous insulin marker

• Low insulin + low C-peptide → $\beta$-cell failure (Type 1 or late Type 2)
• High insulin + low C-peptide → exogenous insulin use
• High insulin + high C-peptide → insulinoma or sulfonylurea use (Step classic differential)

2) Antibodies in Type 1

• Anti-GAD is the most commonly referenced
• Anti-islet cell and anti-insulin can also appear
• Helpful when distinguishing Type 1 from Type 2 in atypical adults (think LADA concept)

3) “Euglycemic DKA” clue

• Patient on SGLT2 inhibitor with DKA symptoms but glucose not sky-high

4) Acanthosis nigricans is a physiology clue

• It’s not just dermatology trivia—it points to hyperinsulinemia/insulin resistance

---

Quick Step-Style Patient Stem Patterns

• Teen, weight loss, polyuria, fruity breath, deep breathing → Type 1 DM with DKA
• Middle-aged with obesity, HTN, high TG, dark velvety neck plaques → Type 2 DM with insulin resistance
• Elderly with infection, very high glucose, confusion, severe dehydration, minimal ketones → HHS
• Diabetic with recurrent UTIs/genital yeast infections after a new med → think SGLT2 inhibitor

---

Rapid Review: What to Memorize Tonight

Type 1

• Autoimmune $\beta$-cell destruction, HLA-DR3/DR4
• Anti-GAD
• Low C-peptide
• DKA-prone
• Must treat with insulin

Type 2

• Insulin resistance → $\beta$-cell failure
• Islet amyloid
• High C-peptide early
• HHS-prone
• Metformin first-line; know GLP-1, SGLT2, sulfonylureas, TZDs